$775 Million is the total value of Soleus Capital Management, L.P.'s 65 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPDR SER TRcall | $126,560,000 | – | 1,408,100 | +100.0% | 16.33% | – |
| ILMN | New | ILLUMINA INC | $21,768,000 | – | 62,300 | +100.0% | 2.81% | – |
| OSUR | New | ORASURE TECHNOLOGIES INC | $20,714,000 | – | 3,055,193 | +100.0% | 2.67% | – |
| HOLX | New | HOLOGIC INC | $17,331,000 | – | 225,600 | +100.0% | 2.24% | – |
| New | ARCELLX INC | $13,876,000 | – | 989,739 | +100.0% | 1.79% | – | |
| SUPN | New | SUPERNUS PHARMACEUTICALS INC | $8,112,000 | – | 251,000 | +100.0% | 1.05% | – |
| TXG | New | 10X GENOMICS INC | $8,074,000 | – | 106,139 | +100.0% | 1.04% | – |
| MIRM | New | MIRUM PHARMACEUTICALS INC | $7,564,000 | – | 343,500 | +100.0% | 0.98% | – |
| EIGR | New | EIGER BIOPHARMACEUTICALS INC | $6,499,000 | – | 783,000 | +100.0% | 0.84% | – |
| NEO | New | NEOGENOMICS INC | $5,589,000 | – | 460,000 | +100.0% | 0.72% | – |
| INMD | New | INMODE LTD | $5,407,000 | – | 146,500 | +100.0% | 0.70% | – |
| SKIN | New | THE BEAUTY HEALTH COMPANY | $3,842,000 | – | 227,612 | +100.0% | 0.50% | – |
| ISRG | New | INTUITIVE SURGICAL INC | $2,353,000 | – | 7,800 | +100.0% | 0.30% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $2,350,000 | – | 69,000 | +100.0% | 0.30% | – |
| New | CYTEK BIOSCIENCES INC | $1,940,000 | – | 180,000 | +100.0% | 0.25% | – | |
| PLRX | New | PLIANT THERAPEUTICS INC | $1,682,000 | – | 240,000 | +100.0% | 0.22% | – |
| OLK | New | OLINK HLDG ABsponsored ads | $953,000 | – | 53,961 | +100.0% | 0.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
| IRADIMED CORP | 16 | Q3 2023 | 5.8% |
| XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
| IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
| SURMODICS INC | 14 | Q3 2023 | 4.7% |
| NATERA INC | 13 | Q3 2023 | 3.9% |
| DEXCOM INC | 13 | Q2 2023 | 4.2% |
| NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
| CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
| LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.